Valuation: Zai Lab Limited

Market Cap 2.73B 21.43B 2.43B 2.27B 2.06B 3.89B 263B 3.93B 27.41B 10.62B 134B 10.26B 10.03B 431B P/E 2026 *
-11x
P/E 2027 * -11x
Enterprise Value 2.27B 17.84B 2.02B 1.89B 1.72B 3.24B 219B 3.27B 22.82B 8.84B 112B 8.54B 8.35B 359B EV / Sales 2026 *
5.21x
EV / Sales 2027 * 4.26x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day-3.46%
1 week-4.77%
Current month-8.09%
1 month-5.53%
3 months+26.05%
6 months+14.41%
Current year+38.97%
1 week 18.91
Extreme 18.91
21
1 month 18.59
Extreme 18.59
21.22
Current year 12.31
Extreme 12.31
21.42
1 year 12.31
Extreme 12.31
26.96
3 years 10.56
Extreme 10.56
35.5
5 years 10.56
Extreme 10.56
84.2
10 years 10.56
Extreme 10.56
151.2
Manager TitleAgeSince
Chief Executive Officer 61 2014-03-31
Director of Finance/CFO 58 2023-07-06
President 62 2022-11-30
Director TitleAgeSince
Chairman 61 2014-03-31
Director/Board Member 83 2016-12-31
Director/Board Member 75 2016-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-3.46%-4.77% - - 2.73B
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
-0.95%-4.05%+20.54%+41.71% 333B
-1.46%-2.89%+10.57%+32.81% 267B
-1.35%-5.43%-6.17%+8.98% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -1.03%-3.54%+26.07%+58.65% 410.8B
Weighted average by Cap. -0.60%-3.54%+29.07%+70.57%

Financials

2026 *2027 *
Net sales 436M 3.43B 388M 362M 330M 622M 41.96B 628M 4.38B 1.7B 21.45B 1.64B 1.6B 68.84B 552M 4.33B 491M 458M 417M 787M 53.08B 794M 5.54B 2.15B 27.13B 2.07B 2.03B 87.08B
Net income -241M -1.89B -214M -200M -182M -343M -23.14B -346M -2.42B -936M -11.83B -904M -884M -37.96B -211M -1.66B -188M -175M -160M -301M -20.29B -304M -2.12B -821M -10.37B -792M -775M -33.29B
Net Debt -458M -3.59B -407M -380M -346M -652M -44B -658M -4.59B -1.78B -22.49B -1.72B -1.68B -72.18B -381M -2.99B -338M -316M -288M -543M -36.61B -548M -3.82B -1.48B -18.72B -1.43B -1.4B -60.06B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Date Price Change Volume
26-10-04 HK$18.97 -3.46% 374,700
26-10-02 HK$19.65 -4.80% 2,272,610
26-09-30 HK$20.64 +1.28% 5,544,000
26-09-29 HK$20.38 +2.31% 5,773,500
26-09-28 HK$19.92 +0.40% 5,094,600
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
24.33USD
Average target price
33.14USD
Spread / Average Target
+36.21%

Quarterly revenue - Rate of surprise